Simcere Zaiming announced FDA Fast Track Designation for SIM0505, a CDH6-targeting antibody–drug conjugate, for platinum-resistant ovarian cancer. The ADC is currently in a global Phase 1 study, with dose-escalation data planned for ASCO 2026
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
U.S. Food and Drug Administration has granted Fast Track Designation to SIM0505, an investigational antibody–drug conjugate developed by Simcere Zaiming, for the treatment of platinum-resistant ovarian cancer, the company announced.
ADC Targeting CDH6 With TOPO1 Payload
SIM0505 is designed as a Cadherin-6 (CDH6)–targeting antibody linked to a proprietary topoisomerase-1 inhibitor payload. According to the company, the antibody–drug conjugate is engineered to deliver broad antitumor activity while enabling rapid systemic clearance and a potentially improved therapeutic window.
Global Partnership with NextCure
In June 2025, Simcere Zaiming entered a strategic collaboration with NextCure for the co-development of SIM0505. Under the agreement, NextCure holds exclusive global rights outside China, Hong Kong, Macau, and Taiwan, while Simcere Zaiming retains rights in those territories.
Ongoing Phase 1 Study in Advanced Solid Tumors
SIM0505 is currently being evaluated in an open-label global Phase 1 study in patients with advanced solid tumors, including ovarian cancer, with a focus on platinum-resistant disease. Dose-escalation data from the trial are planned for presentation at ASCO 2026.
Regulatory Benefits of Fast Track Designation
Fast Track Designation is intended to facilitate development of therapies for serious conditions with unmet medical need. Products receiving this designation are eligible for more frequent interactions with the FDA, rolling review of a Biologics License Application, and potential priority review if supported by clinical data, which may accelerate regulatory timelines.
Reference
FDA Granted Fast Track Designation for SIM0505 (CDH6 ADC) for the Treatment of Ovarian Cancer, 08 April 2026, Simcere
About the Writer
Mahathi Palivela is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.